Introduction {#section5-0004867419885165}
============

Dementia with Lewy bodies (DLB) and Alzheimer's disease (AD) are common forms of dementia in older age, while in Parkinson's disease (PD), development of dementia (Parkinson disease dementia \[PDD\]) occurs in up to 80% of people aged 15--20 years after PD diagnosis. Although the neuropsychiatric and cognitive presentation in PDD is broadly similar to DLB ([@bibr1-0004867419885165]), there are differences including timing of the cognitive, neuropsychiatric and motor symptoms as well as treatment responses and underlying neuropathology ([@bibr20-0004867419885165]).

Structural imaging changes are well characterised in AD with temporoparietal atrophy shown to be a relatively specific disease biomarker ([@bibr44-0004867419885165]). In Lewy body disease, magnetic resonance imaging (MRI) studies have reported greater cortical atrophy in DLB than in PDD ([@bibr2-0004867419885165]; [@bibr37-0004867419885165]), while relative preservation of the medial temporal lobes compared to AD is a consistent finding across both conditions ([@bibr5-0004867419885165]; [@bibr23-0004867419885165]; [@bibr41-0004867419885165]), and significant medial temporal atrophy may indicate concomitant AD-related pathological change ([@bibr5-0004867419885165]). Studies reporting measures of cortical thickness (CTh) in DLB have shown changes in parietal, occipital, temporal and frontal cortices but to a lesser extent than in AD ([@bibr43-0004867419885165]). Cortical thinning has also been shown to be associated with cognitive impairment and dementia in PD ([@bibr22-0004867419885165]; [@bibr35-0004867419885165]; [@bibr45-0004867419885165]), with cortical changes becoming more widespread as the disease progresses.

Our aim was to determine patterns of cortical thinning in a large and well-characterised cohort of older people with AD, DLB and PDD. Atrophic changes in DLB may lie somewhere between AD and PDD, possibly reflecting increased AD co-pathology, but no study has made direct comparisons between all the three dementia groups. We, therefore, utilised FreeSurfer to estimate CTh from structural MRI data to contrast patterns across these groups. We also investigated the clinical correlates of CTh in order to probe the clinical significance of the neurodegenerative process in these conditions.

Methods {#section6-0004867419885165}
=======

Participants {#section7-0004867419885165}
------------

The investigation consisted of 245 individuals gathered from four independent study samples: 76 probable AD ([@bibr29-0004867419885165]), 65 probable DLB ([@bibr28-0004867419885165]), 29 PDD ([@bibr11-0004867419885165]) and 76 older controls. Sample characteristics were the following: study 1 (13 controls, 30 AD, 21 DLB and 16 PDD), study 2 (31 controls, 32 AD and 31 DLB), study 3 (17 controls, 13 AD and 13 DLB) and study 4 (15 controls and 13 PDD). People with probable AD, DLB and PDD were recruited from a community-dwelling population of patients referred to local old age psychiatry, geriatric or neurology services. Older cognitively normal control participants were recruited from patient spouses, friends and volunteers. Approval was sought from the Newcastle, North Tyneside and Northumberland research ethics committees. All participants and/or nearest relatives gave written informed consent. All participants had clinical, cognitive, neurological and neuropsychiatric assessments. Cognitive function was evaluated with the mini-mental state examination (MMSE) ([@bibr16-0004867419885165]) and Cambridge Cognitive Examination (CAMCOG) ([@bibr36-0004867419885165]) tests, while motor parkinsonism was assessed using the unified Parkinson's disease rating scale (UPDRS-III) ([@bibr12-0004867419885165]). For AD, DLB and PDD participants, neuropsychiatric features and cognitive fluctuations were measured with the neuropsychiatric inventory (NPI) ([@bibr6-0004867419885165]) and the clinician assessment of fluctuations (CAF) scale ([@bibr42-0004867419885165]).

Study exclusion criteria across samples included contraindications for MRI, history of alcohol or substance misuse, severe neurological or psychiatric illness, focal brain lesions or presence of other severe or medical illness.

MRI {#section8-0004867419885165}
---

Within 2 months of their respective study assessments, all subjects underwent T1-weighted MRI on a 3-T MRI system (8-channel head coil, Intera Achieva scanner; Philips Medical Systems, Eindhoven, The Netherlands), although there were slight variations in the three-dimensional (3D) MPRAGE sequence across samples. Study 1: sagittal acquisition, matrix 216 (anterior--posterior) × 208 (superior--inferior) × 180 (right--left), repetition time (TR) = 8.3 ms, echo time (TE) = 4.6 ms, flip angle = 8°, SENSE factor = 2, voxel output 1.0 × 1.0 × 1.0 mm^3^. Study 2: sagittal acquisition, matrix 240 × 240 × 180, TR = 9.6 ms, TE = 4.6 ms; flip angle = 8°; SENSE factor = 2, voxel output 1.0 × 1.0 × 1.0 mm^3^. Study 3: sagittal acquisition, matrix 240 × 240 × 150, TR = 9.6 ms, TE = 4.6 ms, flip angle = 8°, SENSE factor = 2, voxel output 0.94 × 0.94 × 1.2 mm^3^. Study 4: sagittal acquisition, matrix 240 × 240 × 180, TR = 8.3 ms, TE = 4.6 ms, flip angle = 8°, SENSE factor = 2, voxel output 1.0 × 1.0 × 1.0 mm^3^. Image volumes were then orientated such that the axial plane was standardised to align with the anterior commissure-posterior commissure (AC-PC) line.

Cortical thickness {#section9-0004867419885165}
------------------

CTh estimates were derived for each participant from cortical surface reconstructions of the T1 images using FreeSurfer (version 5.1), the methodological details of which have been described ([@bibr7-0004867419885165]; [@bibr13-0004867419885165]; [@bibr14-0004867419885165]). In short, the analysis pipeline included non-uniform intensity correction, Talairach transformation, removal of non-brain tissue, segmentation of the white matter (WM) and deep grey matter (GM) structures, triangular tessellation of the WM--GM boundary and then surface warping by tracking intensity gradients to optimally identify the WM--GM and GM--CSF (cerebrospinal fluid)/pial borders ([@bibr7-0004867419885165]; [@bibr13-0004867419885165]). Once cortical models were produced, surface inflation, spherical atlas registration and parcellation of the cerebral cortex into gyral and sulcal structures were performed, ([@bibr32-0004867419885165]) thereby generating a series of surface data. Representations of CTh were then calculated as the closest distance from the WM--GM to pial boundaries at each vertex on the tessellated surface ([@bibr15-0004867419885165]). Examination at each step of image processing was performed to confirm the accuracies of segmentation, WM/pial surfaces and tissue classifications. Images with errors that could not be corrected were excluded. Images were then aligned to a common surface space (MNI 305) and smoothed with a 20-mm full width at half maximum (FWHM) surface--based Gaussian kernel.

Statistical analyses {#section10-0004867419885165}
--------------------

Demographic and behavioural variables were tested for normality and variance homogeneity using Shapiro--Wilk and Levene's tests, respectively. Where applicable, the data were examined using parametric (analysis of variance \[ANOVA\] F, Welch's ANOVA W) and non-parametric (Kruskal--Wallis H, χ^2^) tests and interpreted as significant if *p* ⩽ 0.05. Analysis was conducted using IBM SPSS v.23.0.0.3.

Group effects and behavioural correlates on CTh were assessed vertex wise using the general linear model (GLM). CTh was modelled as a function of each group controlling for the effects of age, gender and MRI sequence (analysis of covariance \[ANCOVA\]), CTh = β~1~.Con + β~2~.AD + β~3~.DLB + β~4~.PDD + β~5~.age + β~6~.gender + β~7~.MRI_sequence + μ + ε (where μ is a constant and ε is error). An *F* contrast was derived to test whether any differences in mean CTh at each vertex existed between the four groups. The resultant surface map, converted to a binary brain mask, defined the surface subspace from which subsequent post hoc analyses were performed to establish which groups differed from each other. In particular, CTh was then modelled within the surface subspace as a function of two groups along with the nuisance covariates, where *T* contrasts generated specific pairwise comparisons (two-tailed *t* tests): Con vs AD, Con vs DLB, Con vs PDD, AD vs DLB, AD vs PDD and DLB vs PDD. Effects of measures (MMSE, CAMCOG~total~, CAMCOG~subscales~, NPI~total~, NPI~hall~ and CAF~total~) on CTh were also investigated separately in AD, DLB and PDD. CTh was modelled as a function of covariate of interest, and where appropriate, controlling for effects of age, gender and MRI sequence. These contrasts tested whether the clinical variables significantly correlated with CTh in these conditions. For all analyses, a false discovery rate (FDR) ([@bibr19-0004867419885165]) probability threshold was applied (*P*~FDR~ ⩽ 0.05), controlling the expected proportion of type I errors among the suprathreshold vertices due to multiple testing across the surfaces.

Results {#section11-0004867419885165}
=======

Demographics and behavioural characteristics {#section12-0004867419885165}
--------------------------------------------

[Table 1](#table1-0004867419885165){ref-type="table"} depicts the study characteristics. Age was broadly similar across groups; however, PDD patients were slightly younger than DLB patients. The male-to-female ratio was much greater in PDD than in AD, DLB and control participants. Global cognition (MMSE, CAMCOG~total~) and executive function were similar across AD, DLB and PDD, whereas memory (CAMCOG~mem~), although comparable between DLB and PDD, was, as expected, more impaired in AD. Neuropsychiatric symptoms, hallucinations and cognitive fluctuations were more severe in DLB and PDD than in AD, while UPDRS-III scores, again as expected, were significantly higher in DLB and PDD relative to AD and controls.

###### 

Demographic and group characteristics.

![](10.1177_0004867419885165-table1)

                                                                            Controls      AD            DLB           PDD           Statistic, *p* value
  ------------------------------------------------------------------------- ------------- ------------- ------------- ------------- ---------------------------------------------------------------------------------------------------
  *n*                                                                       76            75            65            29            
  Age (years)                                                               76.1 ± 5.8    77.9 ± 7.5    78.2 ± 6.4    74.5 ± 5.6    ***F*~3,\ 241~** **=** **3.1, 0.03**^[a](#table-fn5-0004867419885165){ref-type="table-fn"}^
  Gender (m:f)                                                              45:31         47:28         46:19         26:3          **χ**^2^ **=** **9.9, 0.02**
  MMSE                                                                      29.0 ± 1.3    20.4 ± 4.3    20.3 ± 5.2    21.2 ± 4.3    ***H*~3~** **=** **144.3, \<0.001**^[b](#table-fn6-0004867419885165){ref-type="table-fn"}^
  CAMCOG~total~                                                             96.2 ± 4.8    67.4 ± 13.0   67.8 ± 15.2   71.8 ± 14.3   ***H*~3~** **=** **147.1, \<0.001**^[b](#table-fn6-0004867419885165){ref-type="table-fn"}^
  CAMCOG~mem~                                                               23.4 ± 1.7    10.5 ± 4.6    15.5 ± 4.9    17.3 ± 4.8    ***H*~3~** **=** **159.6, \<0.001**^[c](#table-fn7-0004867419885165){ref-type="table-fn"}^
  CAMCOG~exec~                                                              22.3 ± 3.1    13.7 ± 4.6    11.7 ± 5.2    12.4 ± 3.0    ***W*~3,\ 105.6~ = 132.2, \<0.001** ^[d](#table-fn8-0004867419885165){ref-type="table-fn"}^
  NPI~total~                                                                Na            11.7 ± 10.9   18.2 ± 15.2   20.8 ± 14.4   ***H*~2~** **=** **13.2, 0.001**^[e](#table-fn9-0004867419885165){ref-type="table-fn"}^
  NPI~hall~                                                                 Na            0.3 ± 0.8     2.4 ± 2.5     2.3 ± 2.3     ***H*~2~** **=** **62.9, \<0.001**^[e](#table-fn9-0004867419885165){ref-type="table-fn"}^
  CAF~total~                                                                Na            1.7 ± 3.2     6.3 ± 4.4     6.8 ± 3.9     ***H*~2~** **=** **55.5, \<0.001**^[e](#table-fn9-0004867419885165){ref-type="table-fn"}^
  UPDRS-III                                                                 1.6 ± 2.0     3.6 ± 3.7     25.6 ± 12.8   36.9 ± 17.6   ***H*~3~** **=** **175.4, \<0.001**^[f](#table-fn10-0004867419885165){ref-type="table-fn"}^
  Duration of PD (years)                                                    Na            Na            Na            8.9 ± 5.1     
  gCTh~left~                                                                2.44 ± 0.06   2.28 ± 0.06   2.31 ± 0.05   2.40 ± 0.07   ***F*~3,\ 241~** **=** **112.4, \<0.001**^[g](#table-fn11-0004867419885165){ref-type="table-fn"}^
  gCTh~right~                                                               2.45 ± 0.05   2.30 ± 0.06   2.31 ± 0.05   2.40 ± 0.06   ***F*~3,\ 241~** **=** **123.2, \<0.001**^[h](#table-fn12-0004867419885165){ref-type="table-fn"}^
  gCTh~left~ (%)^[i](#table-fn13-0004867419885165){ref-type="table-fn"}^    Na            −6.6%         −5.3%         −1.6%         
  gCTh~right~ (%)^[i](#table-fn13-0004867419885165){ref-type="table-fn"}^   Na            −6.1%         −5.7%         −2.0%         

Values are expressed as mean ± 1 SD.

AD: Alzheimer's disease; DLB: dementia with Lewy bodies; PDD: Parkinson disease dementia; PD: Parkinson's disease; SD: standard deviation; DLB: dementia with Lewy bodies; PDD: Parkinson disease dementia; MMSE: mini-mental state examination; CAMCOG~total~: Cambridge Cognitive Examination total score; CAMCOG~mem~: Cambridge Cognitive Examination memory subdomain; CAMCOG~exec~: Cambridge Cognitive Examination executive function subdomain; NPI~total~: neuropsychiatric inventory total score; NPI~hall~: neuropsychiatric inventory hallucinations; CAF~total~: clinical assessment of fluctuation total score; UPDRS-III: unified Parkinson's disease rating scale (section III); gCTh: global cortical thickness (age, gender and sequence adjusted); Na: not applicable; Ns: not significant (*p* \> 0.05).

Bold text denotes statistical significance.

Post hoc tests:

DLB \> PDD (*p* = 0.05); otherwise Ns (Gabriel's).

Con \> AD, DLB, PDD (*p* \< 0.001); otherwise Ns (Mann--Whitney U).

Con \> AD, DLB, PDD (*p* \< 0.001); DLB, PDD \> AD (*p* \< 0.001); otherwise Ns (Mann--Whitney U).

Con \> AD, DLB, PDD (*p* \< 0.001); otherwise Ns (Games-Howell).

DLB, PDD \> AD (*p* \< 0.03); otherwise Ns (Mann--Whitney U).

DLB, PDD \> Con, AD (*p* \< 0.001); otherwise Ns (Mann--Whitney U).

Con \> AD, DLB, PDD (*p* \< 0.006); PDD \> AD, DLB (*p* \< 0.001), otherwise Ns (Gabriel's).

Con \> AD, DLB, PDD (*p* \< 0.001); PDD \> AD, DLB (*p* \< 0.001), otherwise Ns (Gabriel's).

\% reduction relative to controls.

Cortical thickness {#section13-0004867419885165}
------------------

[Figure 1(a)](#fig1-0004867419885165){ref-type="fig"} illustrates the ANCOVA analysis (*n* = 245), and [Table 2](#table2-0004867419885165){ref-type="table"} summarises the cluster data. Across groups, most of the cerebral cortex showed significant changes in CTh apart from areas of the inferior frontal, pre-post central gyri, paracentral, anterior cingulate, orbitofrontal and medial occipital lobes, where regional CTh was similar. The greatest differences were in the entorhinal cortices. [Figure 1(b)--(f)](#fig1-0004867419885165){ref-type="fig"} present the pairwise post hoc results. Controls vs AD: Cortical thinning was bilaterally diffuse and involved the temporal, parietal and frontal lobes ([Figure 1(b)](#fig1-0004867419885165){ref-type="fig"}). As expected, the most affected areas were the entorhinal cortices, parahippocampal gyri, posterior cingulate, lateral temporal and inferior parietal lobules. [Table 2](#table2-0004867419885165){ref-type="table"} details the significant clusters. Controls vs DLB: Cortical thinning was similarly widespread, i.e. in temporal, parietal and frontal lobes ([Figure 1(c)](#fig1-0004867419885165){ref-type="fig"}). As in AD, areas of greatest change were in the posterior cingulate, lateral temporal and inferior parietal lobules. Entorhinal and parahippocampal changes were also apparent but to a lesser extent than AD. [Table 2](#table2-0004867419885165){ref-type="table"} summarises the cluster data. Controls vs PDD, DLB vs PDD: In PDD, CTh did not differ from healthy controls or participants with DLB ([Figure 1(d)](#fig1-0004867419885165){ref-type="fig"}). DLB vs AD: Areas of significant thinning were confined only to the bilateral entorhinal cortex and left parahippocampal gyrus in AD compared to DLB. PDD vs AD: CTh was reduced in AD relative to PDD in temporal, frontal and parietal regions ([Figure 1(f)](#fig1-0004867419885165){ref-type="fig"}). The most affected structures were the entorhinal cortices ([Table 2](#table2-0004867419885165){ref-type="table"}).

![Regional vertex-wise analyses of cortical thickness (CTh) in controls, AD, DLB and PDD. (a) ANCOVA analysis across groups. (b--f) Subsequent pairwise post hoc tests. Maps are displayed at *P*~FDR~ ⩽ 0.05 (L: left hemisphere; R: right hemisphere).](10.1177_0004867419885165-fig1){#fig1-0004867419885165}

###### 

Cortical thickness results (*P*~FDR~ ⩽ 0.05).

![](10.1177_0004867419885165-table2)

  ------------------------------------------------------------------------------------------------------------------
                      Area     NVtxs     −log~10~ *P*                 MNI             Annotation
  ------------------- -------- --------- ---------------------------- --------------- ------------------------------
  \(a\) *F* test      56,262   110,469   24.7                         −23, −17, −27   L entorhinal

                      1146     2330      5.1                          −7, 24, −12     L medial orbitofrontal

                      54,877   108,443   15.9                         22, −12, −28    R entorhinal

                      1729     4065      3.8                          29, −21, 66     R medial orbitofrontal

                      292      630       2.7                          6, 16, −8       R rostral anterior cingulate

  \(b\) Con vs AD     56,067   110,172   22.9                         −23, −17, −27   L entorhinal

                      1039     2089      5.8                          −8, 26, −13     L medial orbitofrontal

                      54,698   108,056   16.4                         25, −12, −29    R entorhinal

                      285      616       3.0                          6, 12, −9       R medial orbitofrontal

                      560      1350      2.4                          13, −18, 68     R precentral

  \(c\) Con vs DLB    48,173   95,704    9.3                          −58, −60, 5     L middle temporal

                      1146     2330      4.6                          −8, 25, −13     L medial orbitofrontal

                      51,366   101,023   8.8                          54, −52, 32     R inferior parietal

                      1729     4065      4.5                          20, −20, 70     R precentral

                      200      423       2.4                          7, 24, −16      R medial orbitofrontal

  \(d\) Con vs PDD\                      No suprathreshold clusters                   
  DLB vs PDD                                                                          

  \(e\) DLB vs AD     1462     3454      10.5                         −23, −16, −27   L entorhinal

                      328      776       16.4                         24, −13, −28    R entorhinal

  \(f\) PDD vs AD     19,844   39,429    11.2                         −23, −18, −25   L entorhinal

                      7364     13,008    3.6                          −39, 49, 4      L rostral middle frontal

                      113      353       2.3                          −29, 26, 9      L pars triangularis

                      170      266       2.1                          −7, 35, −18     L medial orbitofrontal

                      86       266       2.1                          −33, −22, 18    L insula

                      3164     5988      5.3                          24, −12, −29    R entorhinal

                      867      1928      4.4                          46, −57, 45     R inferior parietal

                      279      446       3.3                          41, 40, 2       R rostral middle frontal

                      137      165       2.8                          43, −75, −6     R lateral occipital
  ------------------------------------------------------------------------------------------------------------------

AD: Alzheimer's disease; DLB: Dementia with Lewy bodies; PDD: Parkinson disease dementia.

Table depicts cluster data, i.e. maximum vertex significance (−log~10~ *P* units), surface area (Area, mm^2^), number of vertices (NVtxs), MNI coordinates (x, y, z; mm) of peak vertex and its annotation. −log~10~ *P* = 1.3, 2.0, 3.0 → *P* = 0.05, 0.01, 0.001, respectively.

To quantify the CTh results, we calculated for each subject, global cortical thickness (gCTh) by averaging across the surface subspaces (left, right) defined by the significant *F*-contrast correcting for age, gender and MR sequence. [Table 1](#table1-0004867419885165){ref-type="table"} depicts the gCTh for each hemisphere and group, where the global profile was controls \> PDD \> DLB \> AD. For gCTh, dementia groups were lower than controls (*p* ⩽ 0.006); PDD was greater than both DLB and AD (*p* \< 0.001) but similar between DLB and AD. Percentage wise, the average (left and right hemispheres combined) reduction in gCTh relative to controls was −6.4%, −5.5% and −1.8% for AD, DLB and PDD, respectively.

[Figure 2](#fig2-0004867419885165){ref-type="fig"} and [Table 3](#table3-0004867419885165){ref-type="table"} summarise the correlation results in AD, DLB and PDD. Significant effects on CTh were found for CAMCOG~total~ and CAMCOG~mem~ in DLB. Lower CAMCOG~total~ scores were associated with a pattern of decreased thickness in the bilateral medial frontal, middle temporal, inferior frontal and inferior parietal as well as right insula, right posterior cingulate, right fusiform and right medial orbitofrontal structures. Lower CAMCOG~mem~ scores were associated with a pattern of decreased thickness in the bilateral medial temporal/temporal poles, left inferior parietal, right cingulate, right superior temporal and right superior/orbito frontal regions. Interestingly, there were no significant relationships between CTh and any of the behavioural measures in AD or PDD.

![Vertex-wise analyses of cortical thickness (CTh) as a function of CAMCOG~total~ and CAMCOG~mem~ in DLB. Maps are displayed for *P*~FDR~ ⩽ 0.05 (L: left hemisphere; R: right hemisphere).](10.1177_0004867419885165-fig2){#fig2-0004867419885165}

###### 

Correlations in AD, DLB and PDD (*P*~FDR~ ⩽ 0.05).

![](10.1177_0004867419885165-table3)

                      Area                             NVtxs    −log~10~ *P*   MNI             Annotation
  ------------------- -------------------------------- -------- -------------- --------------- ------------------------------
  AD                  No suprathreshold correlations                                           
  DLB-CAMCOG~total~   2020                             3858     4.3            −11, 11, 43     L superior frontal
                      263                              583      3.8            −17, 15, −19    L rostral middle frontal
                      1103                             1810     3.4            −33, −80, 30    L inferior parietal
                      512                              1102     3.4            −59, −48, 28    L supramarginal
                      479                              971      3.2            −18, −35, −11   L parahippocampal
                      232                              574      3.1            −39, −18, 33    L precentral
                      104                              241      3.0            −37, 1, −25     L superior temporal
                      277                              628      3.0            −8, −44, 31     L isthmuscingulate
                      409                              754      3.0            −59, −41, −7    L middle temporal
                      117                              254      2.7            −51, 6, 7       L pars opercularis
                      5983                             12,575   4.4            41, −2, −20     R insula
                      3312                             7185     4.2            5, −4, 38       R posterior cingulate
                      2243                             3487     4.1            32, −53, −12    R fusiform
                      603                              1282     3.6            7, 22, −16      R medial orbitofrontal
                      2848                             5600     3.6            35, −53, 38     R inferior parietal
                      2156                             5337     3.2            46, −24, 44     R postcentral
                      239                              577      3.1            26, −55, 5      R lingual
                      969                              1736     2.8            45, 31, 11      R pars triangularis
                      345                              799      2.5            45, −9, 42      R precentral
                      166                              340      2.1            53, −42, 32     R supramarginal
                      105                              202      2.1            32, 29, 40      R rostral middle frontal
  DLB-CAMCOG~mem~     649                              1430     4.3            −38, 4, −28     L superior temporal
                      131                              305      4.3            −18, −34, −12   L parahippocampal
                      106                              230      3.9            −17, 15, −19    L lateral orbitofrontal
                      102                              179      3.4            −41, −75, 31    L inferior parietal
                      38                               115      3.3            −38, −18, 33    L precentral
                      20                               54       3.3            −11, 4, 42      L superior frontal
                      11                               24       3.2            −14, 47, 1      L medial orbitofrontal
                      3984                             8490     6.0            28, −5, −34     R entorhinal
                      751                              1838     3.7            8, 1, 40        R posterior cingulate
                      1195                             2065     3.5            11, 36, 15      R rostral anterior cingulate
                      549                              998      3.0            40, 29, 19      R rostral middle frontal
                      314                              723      3.0            43, −10, 43     R precentral
                      205                              409      2.9            6, 25, −19      R medial orbitofrontal
                      89                               207      2.6            31, 28, −4      R lateral orbitofrontal
                      26                               65       2.5            28, −53, 50     R superior parietal
                      13                               28       3.6            45, −25, 46     R postcentral
  PDD                 No suprathreshold correlations                                           

AD: Alzheimer's disease; DLB: dementia with Lewy bodies; PDD: Parkinson disease dementia; CAMCOG~total~: Cambridge Cognitive Examination total score; CAMCOG~mem~: Cambridge Cognitive Examination memory subdomain; NVtxs: number of vertices.

Discussion {#section14-0004867419885165}
==========

Using an ANCOVA approach followed by pairwise post hoc testing, we investigated the pattern of cortical thinning associated with AD, DLB and PDD. A largely similar pattern of regional cortical thinning was apparent between AD and DLB relative to controls apart from a more severe loss within the entorhinal and parahippocampal structures in AD. In PDD, regional CTh was indistinguishable from controls and DLB, implying either a heterogeneous disease group or one with a degree of 'intermediate' cortical change. By averaging the regional values across the cortical surfaces, we derived measures of gCTh in these groups, where DLB, PDD and AD showed significantly lower gCTh than controls; however, PDD was also greater than DLB and AD, suggesting an 'intermediary' level of global cortical change in PDD. In percentage terms, the average reduction in gCTh compared to controls was −1.8%, −5.5% and −6.4% for PDD, DLB and AD, respectively. Cortical thinning was also associated with cognitive decline in DLB but not in PDD or AD.

In AD, there was a widespread pattern of change in CTh with the lateral temporoparietal and medial temporal areas particularly affected. Cortical thinning in AD has been extensively studied, and our results are consistent with those of previous reports ([@bibr10-0004867419885165]; [@bibr27-0004867419885165]). Relative to controls, a similar picture was associated with DLB, with evidence of some medial temporal thinning but to a lesser extent than AD. When AD and DLB are contrasted, the results suggest a largely shared pattern with the exception of the entorhinal and parahippocampal structures which are more affected in AD. It, therefore, seems that for established AD and DLB with similar levels of global cognition, DLB resembles an AD-like pattern but slightly upstream in terms of cortical thinning. An investigation of prodromal patients found CTh changes relative to controls in AD but not DLB ([@bibr3-0004867419885165]), while longitudinal studies in DLB have shown significantly lower rates of global atrophy compared to AD ([@bibr31-0004867419885165]), with higher rates of atrophy associated with increased concurrent levels of AD co-pathology (β-amyloid) ([@bibr38-0004867419885165]), which appears to support this view.

Cortical degeneration in DLB is heterogeneous and not entirely understood, although a contributory factor may be the presence of coexisting AD-related pathology (β-amyloid, tau). Positive emission tomography (PET) imaging has shown that around 50--60% of people with DLB have significant amyloid deposition ([@bibr9-0004867419885165]), with a high burden predicting a greater rate of cortical atrophy ([@bibr38-0004867419885165]). More recently, tau deposition has been reported in parietal structures in DLB utilising the tau PET tracer ^18^F-AV-1451 ([@bibr21-0004867419885165]; [@bibr40-0004867419885165]). Amyloid-positive DLB cases had marked increases in cortical tau (^18^F-AV-1451 uptake) ([@bibr26-0004867419885165]), and similarly, others found increased temporoparietal and occipital tau binding correlated with global Pittsburgh compound B (PiB) in DLB ([@bibr24-0004867419885165]). It seems that in DLB, people with a higher amyloid burden have additional cortical tau pathology which may then accelerate or contribute to the neurodegenerative process in DLB. Longitudinal studies utilising molecular imaging techniques (tau and amyloid) may offer insight into the evolutionary interaction of these pathologies and their effects on the clinical features, cortical atrophy and outcomes.

The pattern of regional cortical thinning associated with PDD was indistinguishable from healthy controls and patients with DLB, indicating either a heterogeneous group or one with 'intermediate' levels of cortical degeneration. In vivo Alzheimer proteinopathies are less common in PDD than in DLB, where studies have shown higher cortical amyloid deposition ([@bibr4-0004867419885165]) and more transitional tau retention in the former (DLB \> PDD \> controls) ([@bibr40-0004867419885165]). Pathologically, studies have also reported higher cortical β-amyloid and tau loads in DLB compared to PDD, which contribute to cortical neurodegeneration ([@bibr23-0004867419885165]). Therefore, less cortical thinning in PDD than in DLB is consistent with this notion. However, significant cortical thinning has been previously reported in people with mild cognitive impairment and dementia in PD relative to controls, in contrast to our results ([@bibr8-0004867419885165]; [@bibr18-0004867419885165]; [@bibr22-0004867419885165]; [@bibr25-0004867419885165]; [@bibr30-0004867419885165]; [@bibr33-0004867419885165]; [@bibr34-0004867419885165]; [@bibr39-0004867419885165]; [@bibr45-0004867419885165]). Results of structural MRI change have been variable across studies utilising voxelwise, region of interest and CTh measures in PDD. Some report very little change, while others have reported widespread cortical deficits. This may be partly due to the differences in analysis methods. Some reported either uncorrected or Monte Carlo cluster-wise statistics. Cluster-wise approaches provide lower spatial sensitivity and infer a signal somewhere within a cluster. For liberal cluster thresholds, large clusters are often generated where it is then difficult to locate regions representing the true effects, and consequently, the degree of reported change may be overstated. One study that reported vertex-wise FDR-corrected results showed cortical thinning in the frontal, temporal and posterior parietal cortices in PDD (*n* = 15) ([@bibr45-0004867419885165]). Notably, average gCTh in PDD was similar in both studies, CTh (present study) 2.40 ± 0.07 and CTh (Zarei et al.) 2.34 ± 0.05, and was greater than that in DLB, CTh (present study) 2.31 ± 0.05. Variation in results may be partly due to global cognition (MMSE~present~ = 21.2, MMSE~Zarei~ = 18.3), differences in cohort size and comparison group but also highlights disease heterogeneity in PDD. Longitudinal studies with larger sample sizes are needed to accurately assess heterogeneity in PDD.

Cortical thinning was associated with cognitive decline in DLB. Memory (CAMCOG~mem~) related to a CTh pattern involving predominantly the temporal lobes and right frontal regions, whereas for global cognition (CAMCOG~total~), there was also a correlation with parietal and medial frontal areas. We did not detect significant effects between CTh and any of the behavioural measures in either AD or PDD. For AD, the lack of association may be due to floor effects as cortical degeneration occurs much earlier in the disease course. Cholinergic dysfunction is strongly associated with cognitive deficits, fluctuating cognition and visual hallucinations in PDD ([@bibr1-0004867419885165]) and may suggest that strategic loss of key corticopetal afferents from the basal forebrain rather than broad-scale cortical neuronal loss underpins cognitive impairment in this group. Despite similar levels of global cognition, the variation in the pattern and extent of cortical thinning suggests differing mechanisms underlying cognitive decline among AD, DLB and PDD.

Strengths of the study include the following: a large group of probable AD, DLB and PDD patients who were matched for global cognition (MMSE and CAMCOG) and the reporting of FDR-corrected results. While combining datasets has the important advantage of statistical power, one of the disadvantages is in differing assessment procedures. This included the lack of common measures of everyday function and assessment of duration of illness. Duration of illness can be difficult to accurately assess in dementia and, especially, in DLB and PDD where diagnostic delays are common ([@bibr17-0004867419885165]). Other study limitations include the following: diagnoses were clinical rather than neuropathological and there were no measure of tau or amyloid. The effect of using slightly different MRI sequences across the study cohorts did not appear to significantly affect the vertex-wise analyses and, therefore, results but was included as a nuisance covariate for completeness. Further, CTh data from study 2 have been published ([@bibr43-0004867419885165]), while the data from studies 1, 3 and 4 have not. Future work could investigate the patterns of cortical thinning in DLB and PDD, stratified according to high/low amyloid and tau, in order to study the AD pathological burden and their effects on cortical degeneration in Lewy body disease.

Conclusion {#section15-0004867419885165}
==========

Our findings suggest a specific profile of cortical thinning across healthy controls, PDD, DLB and AD. The pattern of structural change in DLB was similar to that in AD, to a slightly lesser extent, while PDD appeared to demonstrate an 'intermediate' degree of regional and global cortical thinning. In these samples, effects of CTh on cognition were confined to DLB that may support the notion of differing processes underlying cognition across Lewy body diseases.
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